Tuesday, April 16, 2024 4:22:39 PM
You're right, it made little difference to the stock price. I do however believe it got a lot of attention from the thousands of oncologists, etc. who attend ASCO for information, few of them are investors. I would be surprised if more than a couple percent who looked at the webcast from the Experts Theater weren't already investors, or at least knowledgeable of NWBO before the conference.
If we have an approval before, the publicity about that may attract far more to attend the webcast, and probably attract many attending ASCO to attend live. Without approval, Newman may be right, they'd cancel, but I believe they would still pay and frankly I still think it's an opportunity to discuss where we are, and where we're going. If I'm right that they'd lose the funds committed to the presentation, I think they'll present.
ASCO Abstract Titles are scheduled to be released on April 24th so if anything has been submitted, we could learn about it then, the actual Abstracts are issued May 23rd. The ASCO Conference is from May 31st to June 4th.
Gary
If we have an approval before, the publicity about that may attract far more to attend the webcast, and probably attract many attending ASCO to attend live. Without approval, Newman may be right, they'd cancel, but I believe they would still pay and frankly I still think it's an opportunity to discuss where we are, and where we're going. If I'm right that they'd lose the funds committed to the presentation, I think they'll present.
ASCO Abstract Titles are scheduled to be released on April 24th so if anything has been submitted, we could learn about it then, the actual Abstracts are issued May 23rd. The ASCO Conference is from May 31st to June 4th.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
